The VITAH trial VITamin D supplementation and cardiac Autonomic tone in Hemodialysis: a blinded, randomized controlled trial

Michelle C Mann, Derek V Exner, Brenda R Hemmelgarn, David A Hanley, Tanvir C Turin, Jennifer M MacRae, Sofia B Ahmed, Michelle C Mann, Derek V Exner, Brenda R Hemmelgarn, David A Hanley, Tanvir C Turin, Jennifer M MacRae, Sofia B Ahmed

Abstract

Background: Patients with end-stage kidney disease (ESKD) have a high rate of mortality and specifically an increased risk of sudden cardiac death (SCD). Impaired cardiac autonomic tone is associated with elevated risk of SCD. Moreover, patients with ESKD are often vitamin D deficient, which we have shown may be linked to autonomic dysfunction in humans. To date, it is not known whether vitamin D supplementation normalizes cardiac autonomic function in the high-risk ESKD population. The VITamin D supplementation and cardiac Autonomic tone in Hemodialysis (VITAH) randomized trial will determine whether intensive vitamin D supplementation therapies improve cardiac autonomic tone to a greater extent than conventional vitamin D supplementation regimens in ESKD patients requiring chronic hemodialysis.

Methods/design: A total of 60 subjects with ESKD requiring thrice weekly chronic hemodialysis will be enrolled in this 2x2 crossover, blinded, randomized controlled trial. Following a 4-week washout period from any prior vitamin D therapy, subjects are randomized 1:1 to intensive versus standard vitamin D therapy for 6 weeks, followed by a 12-week washout period, and finally the remaining treatment arm for 6 weeks. Intensive vitamin D treatment includes alfacalcidiol (activated vitamin D) 0.25 mcg orally with each dialysis session combined with ergocalciferol (nutritional vitamin D) 50 000 IU orally once per week and placebo the remaining two dialysis days for 6 weeks. The standard vitamin D treatment includes alfacalcidiol 0.25 mcg orally combined with placebo each dialysis session per week for 6 weeks. Cardiac autonomic tone is measured via 24 h Holter monitor assessments on the first dialysis day of the week every 6 weeks throughout the study period. The primary outcome is change in the low frequency: high frequency heart rate variability (HRV) ratio during the first 12 h of the Holter recording at 6 weeks versus baseline. Secondary outcomes include additional measures of HRV. The safety of intensive versus conventional vitamin D supplementation is also assessed.

Discussion: VITAH will determine whether an intensive vitamin D supplementation regimen will improve cardiac autonomic tone compared to conventional vitamin D supplementation and will assess the safety of these two supplementation regimens in ESKD patients receiving chronic hemodialysis.

Trial registration: ClinicalTrials.gov, NCT01774812.

Figures

Figure 1
Figure 1
Overview of the VITAH trial.

References

    1. 2013 CORR Report. Treatment of End-Stage Organ Failure in Canada, 2002 to 2011. Ottawa Ontario Canada: Canadian Institute for Health Information; 2013.
    1. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial. 2003;16(2):111–117.
    1. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248. doi: 10.1056/NEJMoa043545.
    1. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samulsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Johnsson E, Zannad F. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407. doi: 10.1056/NEJMoa0810177.
    1. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T. et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192. doi: 10.1016/S0140-6736(11)60739-3.
    1. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550–1559. doi: 10.1681/ASN.2009101047.
    1. Malik M. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043–1065. doi: 10.1161/01.CIR.93.5.1043.
    1. Oikawa K, Ishihara R, Maeda T, Yamaguchi K, Koike A, Kawaguchi H, Tabata Y, Murotani N, Itoh H. Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int J Cardiol. 2009;131(3):370–377. doi: 10.1016/j.ijcard.2007.10.033.
    1. Hathaway DK, Cashion AK, Milstead EJ, Winsett RP, Cowan PA, Wicks MN, Gaber AO. Autonomic dysregulation in patients awaiting kidney transplantation. Am J Kidney Dis. 1998;32(2):221–229. doi: 10.1053/ajkd.1998.v32.pm9708605.
    1. Ranpuria R, Hall M, Chan CT, Unruh M. Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrol Dial Transplant. 2008;23(2):444–449.
    1. Huikuri HV, Makikallio T, Airaksinen KE, Mitrani R, Castellanos A, Myerburg RJ. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol. 1999;34(7):1878–1883. doi: 10.1016/S0735-1097(99)00468-4.
    1. Hayano J, Takahashi H, Toriyama T, Mukai S, Okada A, Sakata S, Yamada A, Ohte N, Kawahara H. Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant. 1999;14(6):1480–1488. doi: 10.1093/ndt/14.6.1480.
    1. Chan CT. Heart rate variability in patients with end-stage renal disease: an emerging predictive tool for sudden cardiac death? Nephrol Dial Transplant. 2008;23(10):3061–3062. doi: 10.1093/ndt/gfn280.
    1. Chan CT, Hanly P, Gabor J, Picton P, Pierratos A, Floras JS. Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int. 2004;65(2):661–665. doi: 10.1111/j.1523-1755.2004.00384.x.
    1. Chan CT, Levin NW, Chertow GM, Larive B, Schulman G, Kotanko P. Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol. 2010;5(10):1821–1827. doi: 10.2215/CJN.03080410.
    1. Routledge HC, Chowdhary S, Townend JN. Heart rate variability–a therapeutic target? J Clin Pharm Ther. 2002;27(2):85–92. doi: 10.1046/j.1365-2710.2002.00404.x.
    1. Reed MJ, Robertson CE, Addison PS. Heart rate variability measurements and the prediction of ventricular arrhythmias. QJM. 2005;98(2):87–95. doi: 10.1093/qjmed/hci018.
    1. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol. 2005;10(1):88–101. doi: 10.1111/j.1542-474X.2005.10101.x.
    1. Lewis MJ. Heart rate variability analysis: a tool to assess cardiac autonomic function. Comput Inform Nurs. 2005;23(6):335–341. doi: 10.1097/00024665-200511000-00011.
    1. Vita G, Bellinghieri G, Trusso A, Costantino G, Santoro D, Monteleone F, Messina C, Savica V. Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney Int. 1999;56(1):232–237. doi: 10.1046/j.1523-1755.1999.00511.x.
    1. Fukuta H, Hayano J, Ishihara S, Sakata S, Mukai S, Ohte N, Ojika K, Yagi K, Matsumoto H, Sohmiya S, Kimura G. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant. 2003;18(2):318–325. doi: 10.1093/ndt/18.2.318.
    1. Vieth R. Why “Vitamin D” is not a hormone, and not a synonym for 1,25-dihydroxy-vitamin D, its analogs or deltanoids. J Steroid Biochem Mol Biol. 2004;89–90(1–5):571–573.
    1. Nigwekar SU, Bhan I, Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012;60(1):139–156. doi: 10.1053/j.ajkd.2011.12.035.
    1. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol. 2012;7(2):358–365. doi: 10.2215/CJN.04040411.
    1. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511. doi: 10.1161/CIRCULATIONAHA.107.706127.
    1. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72(8):1004–1013. doi: 10.1038/sj.ki.5002451.
    1. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, Boehm BO, Dobnig H. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93(10):3927–3935. doi: 10.1210/jc.2008-0784.
    1. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, Wanner C, Boeschoten EW, Brandenburg V. NECOSAD Study Group. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011;26(3):1024–1032. doi: 10.1093/ndt/gfq606.
    1. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, März W, Ritz E, Wanner C. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010;31(18):2253–2261. doi: 10.1093/eurheartj/ehq246.
    1. Selles J, Boland R. Rapid stimulation of calcium uptake and protein phosphorylation in isolated cardiac muscle by 1,25-dihydroxyvitamin D3. Mol Cell Endocrinol. 1991;77(1–3):67–73.
    1. Selles J, Boland R. Evidence on the participation of the 3′,5′-cyclic AMP pathway in the non-genomic action of 1,25-dihydroxy-vitamin D3 in cardiac muscle. Mol Cell Endocrinol. 1991;82(2–3):229–235.
    1. Selles J, Bellido T, Boland R. Modulation of calcium uptake in cultured cardiac muscle cells by 1,25-dihydroxyvitamin D3. J Mol Cell Cardiol. 1994;26(12):1593–1599. doi: 10.1006/jmcc.1994.1179.
    1. Green JJ, Robinson DA, Wilson GE, Simpson RU, Westfall MV. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol. 2006;41(2):350–359. doi: 10.1016/j.yjmcc.2006.05.019.
    1. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, Choi EJ, Chang YS, Bang BK. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006;102(1):c21–29. doi: 10.1159/000088295.
    1. Abdi-Ali A, Nichol DDM, Hemmelgarn BR, MacRae JM, Sola DY, Ahmed SB. 25-hydroxyvitamin D status, arterial stiffness, and the renin angiotensin system in healthy humans. Clin Exp Hypertens. 2013.
    1. Mann MC, Exner DV, Hemmelgarn BR, Turin TC, Sola DY, Ellis L, Ahmed SB. Vitamin D levels are associated with cardiac autonomic activity in healthy humans. Nutrients. 2013;5(6):2114–2127. doi: 10.3390/nu5062114.
    1. Mann MC, Exner DV, Hemmelgarn BR, Sola DY, Turin TC, Ahmed SB. Vitamin D supplementation is associated with improved modulation of cardiac autonomic tone. Int J Cardiol. 2014;172(2):506–8. doi: 10.1016/j.ijcard.2014.01.058.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDGIO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl. 2009;76(113):S1–S130.
    1. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor CL. IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab. 2012;97(4):11467–52.
    1. Manns BJ, Hodsman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD) Am J Kidney Dis. 2010;55(5):800–812. doi: 10.1053/j.ajkd.2010.02.339.
    1. Vaidya A, Sun B, Larson C, Forman JP, Williams JS. Vitamin D3 Therapy Corrects the Tissue Sensitivity to Angiotensin II Akin to the Action of a Converting Enzyme Inhibitor in Obese Hypertensives: An Interventional Study. J Clin Endocrinol Metab. 2012.
    1. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D, D'Souza C, Ursell M, O'Connor P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–1859. doi: 10.1212/WNL.0b013e3181e1cec2.
    1. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009;4 CD005633.
    1. Li Y, Muruve DA, Collins RG, Lee SS, Kubes P. The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol. 2002;32(12):3443–3452. doi: 10.1002/1521-4141(200212)32:12<3443::AID-IMMU3443>;2-F.
    1. Thadhani R, Appelabum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674–84. doi: 10.1001/jama.2012.120.
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81. doi: 10.1056/NEJMra070553.
    1. Kontonopoulous AG, Athyros VG, Didangelos TP, Papagerogiou AA, Avramidis MJ, Mayroudi MC, Karamitsos DT. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic nephropathy. Diabetes Care. 1997;20(3):255–61.
    1. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Effect of paricalcitol on left vantricular mass and function in CKD - the OPERA trial. J Am Soc Nephrol. 2014;25(1):175–86. doi: 10.1681/ASN.2013010103.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅